Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2013

View Archived Issues

Novartis develops new apoptosis regulators

CHF-5074 shows promising clinical efficacy in MCI

Gene linked to albuminuria in rat model

Tau-based immunotherapy for Alzheimer's disease described

LASSbio-1359 reverses development of PAH in rats

Dupilumab leads to improvements in eosinophilic asthma in phase IIa study

Daiichi Sankyo reports on in vivo studies of beta-amyloid peptide vaccine

Researchers develop novel transgenic mouse models of migraine-related disorders

Phase II study planned for CF-101 in uveitis

DSMB approves progress in three Advanced Cell Technology trials

FDA grants orphan designation to LJPC-0712 in Niemann-Pick type C disease

Adynxx receives FDA fast track designation for chronic pain treatment AYX1

ELND-005 granted FDA fast track designation for NPS in Alzheimer's disease

Spectrum Pharmaceuticals gains Marqibo with Talon Therapeutics acquisition

FDA accepts resubmission of NDA for Northera

Alkermes commences phase II study of broad-spectrum oral antipsychotic candidate

Compugen reveals new infrastructure platform for antibody discovery

New cationic polypeptides designed at the University of Minnesota

Rexahn in-licenses oncology drug delivery platform from University of Maryland, Baltimore

Novira Therapeutics prepares novel agents for HBV infection

Team of researchers in Brazil develop new vaccines for Brucella infection

Janssen and Pepscan patent novel polypeptide HIV fusion inhibitors

Novel lisuride analogues disclosed by MAP Pharmaceuticals, now part of Allergan

Alexion commences phase I trial of treatment candidate for MoCD

Recruitment begins in Boehringer Ingelheim's phase I trial of BI-409306

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...